Philip Morris Reports Today. ZYN Just Got a Weapon Nobody Else Has.
The FDA ruling changed what PM can legally say about ZYN. Q2 earnings this morning will show if the market…
The FDA ruling changed what PM can legally say about ZYN. Q2 earnings this morning will show if the market…
Defense demand is undeniable. The margin story is what needs answering now.
Two straight earnings misses set the bar. The debit conversion is underway. Now the synergy math has to show up.
Net earnings up 60% and guidance raised this morning. The stock is still down 22% this year.
A $2 trillion quarter in rated issuance and an AI pivot that is already moving margins.
Value-added services up 25%+ and a $20B buyback. July 28 is the number that matters.
The market is pricing in failure. The data is telling a different story.
A new payments network, the largest credit card issuer in the US, and a stock well below its high.
A new payments network, the largest credit card issuer in the US, and a stock well below its high.
A $2 billion optical market and a Q2 beat streak enter the same week.